Dec 2 (Reuters) - Cytokinetics Inc CYTK.O:
CYTOKINETICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AFICAMTEN FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
CYTOKINETICS INC - PDUFA TARGET ACTION DATE SET FOR SEPTEMBER 26, 2025
CYTOKINETICS INC - FDA NOT PLANNING ADVISORY COMMITTEE MEETING FOR AFICAMTEN NDA
Source text: ID:nGNX4DWm9T
Further company coverage: CYTK.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.